Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 5/20 | 0.64 |
| ▸ | ACE | P12821 | 2/20 | 0.59 |
| ▸ | CTSC | P53634 | 1/20 | 0.59 |
| ▸ | ECE1 | P42892 | 4/20 | 0.58 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1711338 | 1.00 | GHSR (0.64) | GHSRACECTSCECE1ERAP2 | |
| SCHEMBL27601755 | 1.00 | GHSR (0.64) | GHSRACECTSCECE1ERAP2 | |
| SCHEMBL30093010 | 0.99 | GHSR (0.63) | GHSRACECTSCECE1ERAP2 | |
| SCHEMBL21081909 | 0.97 | GHSR (0.69) | GHSRACECTSCECE1ERAP2 | |
| SCHEMBL29782548 | 0.96 | ACE (0.62) | GHSRACECTSCECE1ERAP2 | |
| SCHEMBL30093031 | 0.95 | GHSR (0.59) | GHSRACECTSCECE1ERAP2 | |
| SCHEMBL30093102 | 0.95 | GHSR (0.59) | GHSRACECTSCECE1ERAP2 | |
| SCHEMBL30974046 | 0.94 | GHSR (0.63) | GHSRACEECE1ERAP2 | |
| SCHEMBL2108899 | 0.92 | GHSR (0.74) | GHSRACEECE1ERAP2 | |
| SCHEMBL1712034 | 0.92 | GHSR (0.74) | GHSRACEECE1ERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705045-B2 | compounds comprising a specifier linked to two or more of the same or different leaving groups via a self-eliminating multiple release spacer or spacer system, which compounds upon a single activation step, in particular removal or transformation of the specifier, release two or more leaving groups | SYNTARGA, B.V. (NL) | 2010-04-27 | — | — | US | claimed |
| EP-1370298-B1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | SYNTARGA BV (NL) | 2008-10-08 | — | — | EP | claimed |
| US-7223837-B2 | Anticancer prodrugs, enhance enzymatic activation rates | SYNTARGA B.V. (NL) | 2007-05-29 | — | — | US | claimed |
| US-20060116422-A1 | Prodrugs built as multiple self-elimination-release spacers | SYNTARGA B.V. (NL) | 2006-06-01 | — | — | US | claimed |
| EP-1560599-A1 | PRODRUGS BUILT AS MULTIPLE SELF-ELIMINATION-RELEASE SPACERS | Syntarga B.V. (NL) | 2005-08-10 | — | — | EP | claimed |
| US-20040121940-A1 | Elongated and multiple spacers in activatible produgs | BYONDIS B.V. (NL) | 2004-06-24 | — | — | US | claimed |
| WO-2004043493-A1 | PRODRUGS BUILT AS MULTIPLE SELF-ELIMINATION-RELEASE SPACERS | SYNTARGA B.V. (NL) | 2004-05-27 | — | — | WO | claimed |
| EP-1370298-A1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | Syntarga B.V. (NL) | 2003-12-17 | — | — | EP | claimed |
| WO-2002083180-A1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | SYNTARGA B.V. (NL) | 2002-10-24 | — | — | WO | claimed |
| US-11730817-B2 | Pro-cyclic dinucleotides and pro-cyclic dinucleotide conjugates for cytokine induction | INVIVOGEN (FR) | 2023-08-22 | — | — | US | disclosed |
| US-20230116913-A2 | PRO-CYCLIC DINUCLEOTIDES AND PRO-CYCLIC DINUCLEOTIDE CONJUGATES FOR CYTOKINE INDUCTION | INVIVOGEN (FR) | 2023-04-13 | — | — | US | disclosed |
| US-20220339287-A9 | PRO-CYCLIC DINUCLEOTIDES AND PRO-CYCLIC DINUCLEOTIDE CONJUGATES FOR CYTOKINE INDUCTION | INVIVOGEN (FR) | 2022-10-27 | — | — | US | disclosed |
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | SYNTARGA BV (NL) | 2021-07-06 | — | — | US | disclosed |
| EP-3731874-A1 | PRO-CYCLIC DINUCLEOTIDES AND PRO-CYCLIC DINUCLEOTIDE CONJUGATES FOR CYTOKINE INDUCTION | Invivogen (FR) | 2020-11-04 | — | — | EP | disclosed |
| US-7223837-B2 | Anticancer prodrugs, enhance enzymatic activation rates | SYNTARGA B.V. (NL) | 2007-05-29 | — | — | US | disclosed |
| WO-2007018431-A2 | TRIAZOLE-CONTAINING RELEASABLE LINKERS AND CONJUGATES COMPRISING THE SAME | SYNTARGA B.V. (NL) | 2007-02-15 | — | — | WO | disclosed |
| US-20060116422-A1 | Prodrugs built as multiple self-elimination-release spacers | SYNTARGA B.V. (NL) | 2006-06-01 | — | — | US | disclosed |
| US-20040121940-A1 | Elongated and multiple spacers in activatible produgs | BYONDIS B.V. (NL) | 2004-06-24 | — | — | US | disclosed |
| EP-1370298-A1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | Syntarga B.V. (NL) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002083180-A1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | SYNTARGA B.V. (NL) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730817-B2 | Pro-cyclic dinucleotides and pro-cyclic dinucleotide conjugates for cytokine induction | STING1, CGAS, TLR9 | GHSR 1598/4885ACE 3802/4885CTSC 694/4885 |
| US-20060116422-A1 | Prodrugs built as multiple self-elimination-release spacers | DNPEP, GUSB, APEH | GHSR 264/4885ACE 139/4885CTSC 231/4885 |
| US-20040121940-A1 | Elongated and multiple spacers in activatible produgs | PLG, KLK1, PKM | GHSR 777/4885ACE 2960/4885CTSC 235/4885 |
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | PCNA, DCLRE1A, CDC5L | GHSR 1972/4885ACE 3744/4885CTSC 2832/4885 |
| US-20220339287-A9 | PRO-CYCLIC DINUCLEOTIDES AND PRO-CYCLIC DINUCLEOTIDE CONJUGATES FOR CYTOKINE INDUCTION | STING1, CGAS, TLR9 | GHSR 1598/4885ACE 3802/4885CTSC 694/4885 |
| US-20230116913-A2 | PRO-CYCLIC DINUCLEOTIDES AND PRO-CYCLIC DINUCLEOTIDE CONJUGATES FOR CYTOKINE INDUCTION | STING1, CGAS, TLR9 | GHSR 1598/4885ACE 3802/4885CTSC 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.